Do analysts recommend STRO or AADI?

Sutro Biopharma currently has a consensus price target of $52.44, suggesting a potential upside of 129.22%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe Sutro Biopharma is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sutro Biopharma 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 2.92 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor STRO or AADI?

In the previous week, Sutro Biopharma had 3 more articles in the media than Aadi Bioscience. MarketBeat recorded 4 mentions for Sutro Biopharma and 1 mentions for Aadi Bioscience. Sutro Biopharma's average media sentiment score of 1.26 beat Aadi Bioscience's score of -0.71 indicating that Sutro Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sutro Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aadi Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts rate AUTL or AADI?

Autolus Therapeutics currently has a consensus price target of $8.75, indicating a potential upside of 503.45%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Autolus Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Autolus Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor AUTL or AADI?

In the previous week, Autolus Therapeutics had 2 more articles in the media than Aadi Bioscience. MarketBeat recorded 3 mentions for Autolus Therapeutics and 1 mentions for Aadi Bioscience. Autolus Therapeutics' average media sentiment score of 1.16 beat Aadi Bioscience's score of -0.71 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aadi Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts prefer AADI or ABEO?

Abeona Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 214.05%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Abeona Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Does the media refer more to AADI or ABEO?

In the previous week, Abeona Therapeutics had 1 more articles in the media than Aadi Bioscience. MarketBeat recorded 2 mentions for Abeona Therapeutics and 1 mentions for Aadi Bioscience. Abeona Therapeutics' average media sentiment score of 1.04 beat Aadi Bioscience's score of -0.71 indicating that Abeona Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aadi Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Abeona Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AADI or EOLS?

Evolus has a consensus target price of $16.00, suggesting a potential upside of 167.56%. Given Evolus' stronger consensus rating and higher probable upside, analysts clearly believe Evolus is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Evolus 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is AADI or EOLS more profitable?

Evolus has a net margin of -14.39% compared to Aadi Bioscience's net margin of -246.06%. Evolus' return on equity of 0.00% beat Aadi Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Aadi Bioscience -246.06% -71.87% -57.28% Evolus -14.39% N/A -19.03%

Does the media refer more to AADI or EOLS?

In the previous week, Evolus had 1 more articles in the media than Aadi Bioscience. MarketBeat recorded 2 mentions for Evolus and 1 mentions for Aadi Bioscience. Evolus' average media sentiment score of 1.52 beat Aadi Bioscience's score of -0.71 indicating that Evolus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aadi Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Evolus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend AADI or CMPX?

Compass Therapeutics has a consensus price target of $12.25, suggesting a potential upside of 491.79%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Compass Therapeutics 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.87

Does the media refer more to AADI or CMPX?

In the previous week, Compass Therapeutics had 3 more articles in the media than Aadi Bioscience. MarketBeat recorded 4 mentions for Compass Therapeutics and 1 mentions for Aadi Bioscience. Compass Therapeutics' average media sentiment score of 0.97 beat Aadi Bioscience's score of -0.71 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aadi Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Compass Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aadi Bioscience (AADI) Competitors

$3.71 -0.12 (-3.13%)

As of 07/24/2026

Compare

AADI vs. STRO, AUTL, ABEO, EOLS, and CMPX

Should you buy Aadi Bioscience stock or one of its competitors? MarketBeat compares Aadi Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aadi Bioscience include Sutro Biopharma (STRO), Autolus Therapeutics (AUTL), Abeona Therapeutics (ABEO), Evolus (EOLS), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry.

How does Aadi Bioscience compare to Sutro Biopharma?

Sutro Biopharma (NASDAQ:STRO) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

In the previous week, Sutro Biopharma had 3 more articles in the media than Aadi Bioscience. MarketBeat recorded 4 mentions for Sutro Biopharma and 1 mentions for Aadi Bioscience. Sutro Biopharma's average media sentiment score of 1.26 beat Aadi Bioscience's score of -0.71 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aadi Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Aadi Bioscience has lower revenue, but higher earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	3.70	-$191.09M	-$11.04	N/A
Aadi Bioscience	$25.07M	3.65	-$65.76M	-$2.35	N/A

Sutro Biopharma currently has a consensus price target of $52.44, suggesting a potential upside of 129.22%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe Sutro Biopharma is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 1.8% of Sutro Biopharma shares are owned by insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sutro Biopharma has a net margin of -154.21% compared to Aadi Bioscience's net margin of -246.06%. Sutro Biopharma's return on equity of 0.00% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-154.21%	N/A	-69.20%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Sutro Biopharma has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

Summary

Sutro Biopharma beats Aadi Bioscience on 12 of the 17 factors compared between the two stocks.

How does Aadi Bioscience compare to Autolus Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

Autolus Therapeutics currently has a consensus price target of $8.75, indicating a potential upside of 503.45%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Autolus Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Autolus Therapeutics had 2 more articles in the media than Aadi Bioscience. MarketBeat recorded 3 mentions for Autolus Therapeutics and 1 mentions for Aadi Bioscience. Autolus Therapeutics' average media sentiment score of 1.16 beat Aadi Bioscience's score of -0.71 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aadi Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aadi Bioscience has lower revenue, but higher earnings than Autolus Therapeutics. Aadi Bioscience is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$92.62M	4.17	-$287.53M	-$1.09	N/A
Aadi Bioscience	$25.07M	3.65	-$65.76M	-$2.35	N/A

Autolus Therapeutics has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

Aadi Bioscience has a net margin of -246.06% compared to Autolus Therapeutics' net margin of -311.98%. Aadi Bioscience's return on equity of -71.87% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Summary

Autolus Therapeutics beats Aadi Bioscience on 13 of the 17 factors compared between the two stocks.

How does Aadi Bioscience compare to Abeona Therapeutics?

Aadi Bioscience (NASDAQ:AADI) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market.

Abeona Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Abeona Therapeutics' return on equity of -53.98% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Abeona Therapeutics	N/A	-53.98%	-38.52%

Abeona Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 214.05%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Abeona Therapeutics	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Abeona Therapeutics had 1 more articles in the media than Aadi Bioscience. MarketBeat recorded 2 mentions for Abeona Therapeutics and 1 mentions for Aadi Bioscience. Abeona Therapeutics' average media sentiment score of 1.04 beat Aadi Bioscience's score of -0.71 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aadi Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Abeona Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abeona Therapeutics has lower revenue, but higher earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	3.65	-$65.76M	-$2.35	N/A
Abeona Therapeutics	$5.82M	59.24	$71.18M	$0.97	6.24

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by company insiders. Comparatively, 7.1% of Abeona Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Abeona Therapeutics beats Aadi Bioscience on 14 of the 16 factors compared between the two stocks.

How does Aadi Bioscience compare to Evolus?

Aadi Bioscience (NASDAQ:AADI) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Evolus has a consensus target price of $16.00, suggesting a potential upside of 167.56%. Given Evolus' stronger consensus rating and higher probable upside, analysts clearly believe Evolus is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by insiders. Comparatively, 5.0% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Evolus has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

Evolus has a net margin of -14.39% compared to Aadi Bioscience's net margin of -246.06%. Evolus' return on equity of 0.00% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Evolus	-14.39%	N/A	-19.03%

Evolus has higher revenue and earnings than Aadi Bioscience. Evolus is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	3.65	-$65.76M	-$2.35	N/A
Evolus	$297.18M	1.33	-$51.64M	-$0.67	N/A

In the previous week, Evolus had 1 more articles in the media than Aadi Bioscience. MarketBeat recorded 2 mentions for Evolus and 1 mentions for Aadi Bioscience. Evolus' average media sentiment score of 1.52 beat Aadi Bioscience's score of -0.71 indicating that Evolus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aadi Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Evolus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Evolus beats Aadi Bioscience on 13 of the 16 factors compared between the two stocks.

How does Aadi Bioscience compare to Compass Therapeutics?

Aadi Bioscience (NASDAQ:AADI) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Aadi Bioscience has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	3.65	-$65.76M	-$2.35	N/A
Compass Therapeutics	N/A	N/A	-$66.49M	-$0.41	N/A

Compass Therapeutics has a consensus price target of $12.25, suggesting a potential upside of 491.79%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

Compass Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Compass Therapeutics' return on equity of -39.75% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Compass Therapeutics	N/A	-39.75%	-35.29%

In the previous week, Compass Therapeutics had 3 more articles in the media than Aadi Bioscience. MarketBeat recorded 4 mentions for Compass Therapeutics and 1 mentions for Aadi Bioscience. Compass Therapeutics' average media sentiment score of 0.97 beat Aadi Bioscience's score of -0.71 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aadi Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Compass Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Compass Therapeutics beats Aadi Bioscience on 12 of the 16 factors compared between the two stocks.

Get Aadi Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AADI vs. The Competition

Export

Metric	Aadi Bioscience	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$91.63M	$975.11M	$6.87B	$12.26B
Dividend Yield	N/A	4.84%	2.67%	9.79%
P/E Ratio	-1.63	1.53	27.14	23.64
Price / Sales	3.65	105.75	517.06	88.99
Price / Cash	N/A	20.06	50.54	59.64
Price / Book	0.86	8.47	10.28	6.07
Net Income	-$65.76M	-$2.70M	$3.60B	$331.99M
7 Day Performance	-4.63%	-2.29%	-1.27%	-0.63%
1 Month Performance	-15.49%	-3.97%	-0.37%	-2.00%
1 Year Performance	91.24%	27.39%	18.30%	13.62%

Aadi Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AADI Aadi Bioscience	N/A	$3.71 -3.1%	N/A	+90.5%	$91.63M	$25.07M	N/A	40
STRO Sutro Biopharma	3.0597 of 5 stars	$23.00 +1.8%	$52.44 +128.0%	+150.1%	$374.33M	$102.48M	N/A	240	News Coverage Positive News
AUTL Autolus Therapeutics	2.3685 of 5 stars	$1.47 +4.6%	$8.75 +497.3%	-45.1%	$372.62M	$92.62M	N/A	330	Positive News
ABEO Abeona Therapeutics	3.5657 of 5 stars	$6.53 +0.8%	$19.00 +191.0%	-9.0%	$369.33M	$5.82M	6.73	90
EOLS Evolus	2.7082 of 5 stars	$5.80 +4.5%	$16.00 +175.9%	-38.0%	$365.17M	$297.18M	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AADI) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aadi Bioscience (AADI) Competitors

AADI vs. STRO, AUTL, ABEO, EOLS, and CMPX

How does Aadi Bioscience compare to Sutro Biopharma?

Summary

How does Aadi Bioscience compare to Autolus Therapeutics?

Summary

How does Aadi Bioscience compare to Abeona Therapeutics?

Summary

How does Aadi Bioscience compare to Evolus?

Summary

How does Aadi Bioscience compare to Compass Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI vs. The Competition

Aadi Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aadi Bioscience (AADI) Competitors

AADI vs. STRO, AUTL, ABEO, EOLS, and CMPX

How does Aadi Bioscience compare to Sutro Biopharma?

Does the media favor STRO or AADI?

Which has preferable valuation and earnings, STRO or AADI?

Do analysts recommend STRO or AADI?

Do institutionals & insiders hold more shares of STRO or AADI?

Is STRO or AADI more profitable?

Which has more risk and volatility, STRO or AADI?

Summary

How does Aadi Bioscience compare to Autolus Therapeutics?

Do analysts rate AUTL or AADI?

Does the media favor AUTL or AADI?

Do insiders & institutionals believe in AUTL or AADI?

Which has higher earnings and valuation, AUTL or AADI?

Which has more volatility & risk, AUTL or AADI?

Is AUTL or AADI more profitable?

Summary

How does Aadi Bioscience compare to Abeona Therapeutics?

Which has more volatility & risk, AADI or ABEO?

Is AADI or ABEO more profitable?

Do analysts prefer AADI or ABEO?

Does the media refer more to AADI or ABEO?

Which has better earnings & valuation, AADI or ABEO?

Do insiders and institutionals hold more shares of AADI or ABEO?

Summary

How does Aadi Bioscience compare to Evolus?

Do analysts recommend AADI or EOLS?

Do institutionals & insiders hold more shares of AADI or EOLS?

Which has more volatility and risk, AADI or EOLS?

Is AADI or EOLS more profitable?

Which has preferable valuation & earnings, AADI or EOLS?

Does the media refer more to AADI or EOLS?

Summary

How does Aadi Bioscience compare to Compass Therapeutics?

Which has better valuation and earnings, AADI or CMPX?

Do analysts recommend AADI or CMPX?

Do institutionals and insiders hold more shares of AADI or CMPX?

Which has more risk & volatility, AADI or CMPX?

Is AADI or CMPX more profitable?

Does the media refer more to AADI or CMPX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI vs. The Competition

Aadi Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools